Patents Represented by Attorney Jason C. Fedon
-
Patent number: 8071731Abstract: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.Type: GrantFiled: April 1, 2008Date of Patent: December 6, 2011Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Volker Germaschewski
-
Patent number: 8017115Abstract: A method of promoting oligodendrocyte survival in a human suffering from, or at risk of developing, stroke or other neurological diseases utilizes anti-MAG antibodies or functional fragments of such antibodies.Type: GrantFiled: February 2, 2004Date of Patent: September 13, 2011Assignee: Glaxo Group LimitedInventors: Elaine Alison Irving, Mary Vinson
-
Patent number: 8003101Abstract: The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM.Type: GrantFiled: May 9, 2007Date of Patent: August 23, 2011Assignee: GlaxoSmithKline LLCInventors: Paul F. Life, Edward S. Rees, Andrew D. Rhodes
-
Patent number: 7858753Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: March 29, 2005Date of Patent: December 28, 2010Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Alexandre Eon-Duval, Volker Germaschewski, Christopher Plumpton, Nicholas Timothy Rapson, Michael Robert West
-
Patent number: 7696320Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: GrantFiled: January 11, 2006Date of Patent: April 13, 2010Assignee: Domantis LimitedInventors: Olga Ignatovich, Steve Holmes, Roland Beckmann, Rudolf M. T. de Wildt
-
Patent number: 7662633Abstract: Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.Type: GrantFiled: June 22, 2006Date of Patent: February 16, 2010Assignee: GlaxoSmithKline LLCInventors: Simon Barry, Carmel Horgan, Steven Ludbrook
-
Patent number: 7612183Abstract: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.Type: GrantFiled: August 5, 2003Date of Patent: November 3, 2009Assignee: Glaxo Group LimitedInventors: Jonathan Henry Ellis, Volker Germaschewski
-
Patent number: 7557191Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.Type: GrantFiled: October 12, 2006Date of Patent: July 7, 2009Assignee: SmithKline Beecham CorporationInventors: Julie A. Abrahamson, Connie L Erickson-Miller, Kristine K. Kikly, Bruce Bochner, Robert Schleimer
-
Patent number: 7504232Abstract: Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.Type: GrantFiled: March 23, 2001Date of Patent: March 17, 2009Assignee: Smithkline Beecham CorporationInventors: Simon Barry, Carmel Horgan, Steven Ludbrook
-
Patent number: 7361734Abstract: A Staphylococcus aureus S8 native crystalline structure and a Staphylococcus aureus S8 mode of binding with rRNA were identified.Type: GrantFiled: October 15, 2002Date of Patent: April 22, 2008Assignee: SmithKline Beecham CorporationInventors: Nestor O. Concha, Richard R. Gontarek, Cheryl A. Janson
-
Patent number: 7348009Abstract: The present invention provides a novel treatment for allergy comprising a recombinant allergen with reduced enzymatic activity, thereby reducing the potential for an allergic response upon contact with a wild-type allergen.Type: GrantFiled: November 16, 1998Date of Patent: March 25, 2008Assignee: SmithKline Beecham Biologicals, s.a.Inventors: Claudine Bruck, Alex Bollen, Paul Jacobs, Marc Georges Francis Massaer
-
Patent number: 7202071Abstract: The invention provides pth polypeptides and polynucleotides encoding pth polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pth polypeptides to screen for antibacterial compounds.Type: GrantFiled: May 14, 2003Date of Patent: April 10, 2007Assignee: SmithKline Beecham CorporationInventors: Sanjoy Biswas, James Raymond Brown, Christine Debouck, Deborah Dee Jaworski, Elizabeth Jane Lawlor, Jeffrey Mooney, Lisa Kathleen Shilling, Min Wang, Richard Lloyd Warren, Magdalena Zalacain, Yi Yi Zhong, John Peter Throup, Karen Anne Ingraham, Alison Frances Chalker, David John Holmes, Christopher Michael Traini
-
Patent number: 7173117Abstract: The present invention relates to codon optimised polynucleotides which are efficiently expressed in mammalian cells and encode insect proteins from Dermaphagoids dust mite. In particular, the optimised codon polynucleotides encode a protein from Dermaphagoides pteronyssinus, such as DerP1 or proDerP1. The present invention also provides methods of preparing pharmaceutical compositions comprising the expression of the codon optimised polynucleotides, and vectors and transformed host cells comprising them.Type: GrantFiled: June 7, 2001Date of Patent: February 6, 2007Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Alex Bollen, Paul Jacobs, Alain Jacquet, Marc Georges Francis Massaer
-
Patent number: 7144703Abstract: Novel vaccine compositions are provided comprising a hepatitis B antigen formulated with aluminium phosphate. The vaccine compositions may additionally contain an inactivated hepatitis A virus, aluminium hydroxide and formol. The combined hepatitis A and B vaccine formulations can, if desired, be administered to human subjects in a 2 dose regimen. Suitable formulations are illustrated.Type: GrantFiled: July 1, 2004Date of Patent: December 5, 2006Assignee: SmithKline Beecham Biologicals, s.a.Inventors: Claude Artois, Michael J Clark, Stefan Gabriel Jozef Thoelen, Clothilde Thiriart
-
Patent number: 7112331Abstract: The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella infections. The compositions of the invention comprise the protein encoded by VZV gene 63 or an immunologically active derivative thereof. The invention further relates to compositions containing DNA or RNA corresponding to VZV gene 63.Type: GrantFiled: February 4, 1997Date of Patent: September 26, 2006Assignees: SmithKline Beecham Biologicals, s.a., University of LiegeInventors: Bernard Rentier, Catherine Sadzot
-
Patent number: 6929920Abstract: Methods of determining Chronic Obstructive Pulmonary Disease (COPD) severity in patients which comprises measuring the concentration of soluble E-cadherin (sE-cadherin) in the patient's urine and/or blood serum and determining the extent of severity by reference to correlation graphs, a method of treating patients with COPD, methods for determining the responsiveness of said patients to said treatment and a prognostic product for detecting the concentration of sE-cadherin in urine and/or blood serum.Type: GrantFiled: May 25, 2000Date of Patent: August 16, 2005Assignee: Glaxo Group LimitedInventor: Michael Robert West
-
Patent number: 6838255Abstract: The invention provides MurC polypeptides and polynucleotides encoding MurC polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing MurC polypeptides to screen for antibacterial compounds.Type: GrantFiled: June 23, 1998Date of Patent: January 4, 2005Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Martin Karl Russell Burnham, Nicola Gail Wallis
-
Patent number: 6770462Abstract: A method for inserting a cassette into a nucleic acid molecule to produce a modified nucleic acid molecule, e.g., a nucleic acid-cassette fusion, is described. The method involves the use of polymerase chain reaction, thereby permitting precise targeting of the desired site in the molecule, but does not require ligation. Also described is the use of this method for high throughput screening the resulting modified nucleic acid molecules.Type: GrantFiled: November 5, 2001Date of Patent: August 3, 2004Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Alison F. Chalker, David J. Holmes, Robert Dwayne Lunsford, James Yigong Ge
-
Patent number: RE39792Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium. REEXAMINATION RESULTS The questions raised in reexamination request no. 90/006656, filed Jun. 2, 2003 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.Type: GrantFiled: November 22, 2004Date of Patent: August 21, 2007Assignee: SmithKline Beecham CorporationInventors: Michael J. Keen, Nicholas T. Rapson
-
Patent number: RE41974Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium.Type: GrantFiled: December 15, 2006Date of Patent: November 30, 2010Assignee: GlaxoSmithKline LLCInventors: Michael John Keen, Nicholas Timothy Rapson